Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps
Bousquet, Jean × Bachert, Claus Bernstein, Jonathan Canonica, G Walter Carr, Warner Dahl, Ronald Demoly, Pascal Devillier, Philippe Hellings, Peter Fokkens, Wytske Klimek, Ludger Lieberman, Phil Meltzer, Eli Price, David Ryan, Dermot Wahn, Ulrich #
Expert Opinion on Pharmacotherapy vol:16 issue:6 pages:913-28
Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.